Department of Orthopedic Surgery, Seoul National University Boramae Hospital, Seoul National University College of Medicine, 20 Boramae-Ro, 5-Gil, Dongjak-Gu, Seoul, 156-707, South Korea.
Cell Tissue Res. 2013 Jul;353(1):41-52. doi: 10.1007/s00441-013-1619-5. Epub 2013 Apr 30.
Mesenchymal stem cells (MSCs) can be obtained from various sources. MSCs from different origins appear to have different preferences for differentiation. In this study, we have compared the in vivo osteogenic potential of adult MSCs from adipose tissue (AT) and bone marrow (BM) with fetal MSCs from umbilical cord (UC) and umbilical cord blood (UCB) by using a rat critical-sized femoral defect model. We have also sought to determine whether pretreatment with an osteogenic medium promotes osteogenesis in MSCs. Study groups were divided as follows: (1) defect only, (2) scaffold only, (3) AT MSCs in scaffolds, (4) BM MSCs in scaffolds, (5) UC MSCs in scaffolds and (6) UCB MSCs in scaffolds. Groups with MSCs were further divided with respect to their pretreatment. At 12 weeks after surgery, in vivo osteogenesis was measured radiographically and by micro-computed tomography (CT). Based on quantitative assessment by micro-CT, no significant difference of the mean bone volume fraction value (BV/TV) was seen between adult MSCs (AT and BM MSCs) and fetal MSCs (UC and UCB MSCs). The mean BV/TVs were significantly higher in non-pretreated BM MSC (14.2±1.4%) and UCB MSC (14.0±1.2%) and pretreated UC MSC (14.8±2.0%) than in those with the scaffold only (11.3±1.3%; P<0.05). In addition, AT (from 10.4±1.2% to 13.1±2.2%) and UC (from 10.3±0.7% to 14.8±2.0%) MSCs from solid tissues showed a significant increase in the mean BV/TV with pretreatment (P<0.05). In contrast, BM MSC (from 14.2±1.4% to 10.9±1.2%) and UCB MSC (from 14.0±1.2% to 11.6±1.0%) from non-solid tissues showed a significant decrease with pretreatment (P<0.05).
间充质干细胞（MSCs）可从多种来源获得。不同来源的 MSCs 似乎对分化有不同的偏好。在这项研究中，我们通过使用大鼠临界尺寸股骨缺损模型，比较了来自脂肪组织（AT）和骨髓（BM）的成体 MSCs 与来自脐带（UC）和脐带血（UCB）的胎儿 MSCs 的体内成骨潜能。我们还试图确定成骨培养基预处理是否能促进 MSCs 的成骨作用。研究组分为以下几类：（1）仅缺陷，（2）仅支架，（3）支架中的 AT MSCs，（4）支架中的 BM MSCs，（5）支架中的 UC MSCs 和（6）支架中的 UCB MSCs。MSCs 组根据预处理进行了进一步细分。手术后 12 周，通过 X 射线和微计算机断层扫描（CT）测量体内成骨情况。基于微 CT 的定量评估，成体 MSCs（AT 和 BM MSCs）与胎儿 MSCs（UC 和 UCB MSCs）之间的平均骨体积分数值（BV/TV）没有显著差异。未预处理的 BM MSC（14.2±1.4%）和 UCB MSC（14.0±1.2%）和预处理的 UC MSC（14.8±2.0%）的平均 BV/TV 明显高于仅支架组（11.3±1.3%；P<0.05）。此外，来自实体组织的 AT（从 10.4±1.2%到 13.1±2.2%）和 UC（从 10.3±0.7%到 14.8±2.0%）MSCs 在预处理后平均 BV/TV 显著增加（P<0.05）。相比之下，来自非实体组织的 BM MSC（从 14.2±1.4%到 10.9±1.2%）和 UCB MSC（从 14.0±1.2%到 11.6±1.0%）在预处理后平均 BV/TV 显著降低（P<0.05）。
